



FONDAZIONE
MONDINO
Istituto Neurologico Nazionale
a Carattere Scientifico | IRCCS



SEMINARIO (SEM05/26)

RECENT ADVANCES IN SMALL MOLECULE THERAPEUTICS AND BLOOD-BASED BIOMARKER ANALYSIS FOR ALS DISEASE

with **Emanuele BURATTI**

Introduced by **Luca DIAMANTI**

23.09.2026

Aula Berluschi 14.00 -17.00

Fondazione Istituto Neurologico Nazionale
IRCCS G. Mondino, Pavia

*Since beginning his postdoctoral work, the principal areas of **Dr. Buratti's** expertise have been the investigation of RNA binding proteins/structure and their influence on translation and alternative splicing processes.*

In 2001, as part of a research project on Cystic Fibrosis, he identified nuclear protein TDP-43 as a potential CFTR exon 9 pre-mRNA splicing regulator.

As a result, in the following years he has performed several basic studies on the biochemical and functional properties of this protein that have been of great advantage to the scientific community when its role in neurodegeneration was first reported in 2006.

*Since then, **Dr. Buratti** research has primarily focused on investigating the potential pathophysiological role played by TDP-43 in Frontotemporal Dementia and Amyotrophic Lateral Sclerosis, and in better understanding the functional roles played by this protein (ie. microRNA biogenesis and splicing regulation, shuttling nuclear/cytosplamic properties, autoregulatory processes, and so forth).*

REFERENTE SCIENTIFICO

Dr. Luca DIAMANTI

Neurologia | IRCCS Fondazione Mondino Pavia



SEGRETERIA ORGANIZZATIVA
SERVIZIO EDUCATION & TRAINING FONDAZIONE MONDINO

formazione@mondino.it

FM +39 0382 380299

STUDIO C +39 0382 21424

 351.8055151

PROGETTO FORMATIVO NON ACCREDITATO E.C.M.

Non consentirà l'acquisizione di crediti formativi E.C.M.

LA PARTECIPAZIONE AI LAVORI È LIMITATA
AD UN NUMERO MASSIMO DI 100 ISCRITTI